Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Teriparatide injection - Eli Lilly

Drug Profile

Teriparatide injection - Eli Lilly

Alternative Names: Forsteo; Forteo; hPTH 1-34; LY 333334; MN 10T; Parathar; Parathyroid hormone (1-34); PTH; Teriparatide; Teriparatide acetate

Latest Information Update: 09 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Eli Lilly; Eli Lilly and Company
  • Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Male osteoporosis; Osteoporosis; Postmenopausal osteoporosis
  • Market Withdrawal Hypoparathyroidism
  • Discontinued Fracture

Most Recent Events

  • 09 Jul 2019 Discontinued - Phase-III for Fracture treatment in South America, Spain, Sweden, Canada, Norway, Lithuania, Latvia, Hong Kong, Finland, Estonia, Denmark, Switzerland, Romania, Japan, Taiwan, Poland, Netherlands, India, Hungary, Greece, Germany, France, Croatia, Turkey, Israel, New Zealand, Australia, South Korea, Belgium, USA (SC) (Eli Lilly pipeline, July 2019)
  • 16 Sep 2016 Pharmacodynamics data from the EUROFORS study presented at the 38th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2016)
  • 17 Jun 2015 EudraCT2006-004110-40 - Added trial info
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top